ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
20.132,85
-0,44%
S&P 500
5.836,22
0,16%
Dow Jones
42.297,12
0,86%
Euro vs US Dollar
1,02469
-0,17%
Bitcoin
94.925,79
0,44%
Pepperstone
Advertisement
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ

  6. C4 Therapeutics Inc (CCCC) Börsenkurse

C4 Therapeutics Inc

C4 Therapeutics Inc (CCCC)

NASDAQ
3,50
-0,165
(-4,50%)
Geschlossen 14 Januar 10:00PM
Verzögert um 15 Minuten
3,48
-0,02
(-0,57%)
Nach Börsenschluss: 1:32AM
Verzögert um 15 Minuten

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Premium

Wichtige Statistiken und Details

Current Price
3,48
Gebot
3,40
Fragen
3,54
Volumen
2.172.918
3,38 Tagesbereich 3,60
3,43 52-Wochen-Bereich 11,88
Marktkapitalisierung
245,65M
Handelsende
3,665
Handelsbeginn
3,58
Letzte Trade
1
@
3.54
Letzter Handelszeitpunkt
Finanzvolumen
US$ 7.472.793
VWAP
3,4391
Durchschnittliches Volumen (3 Mio.)
1.436.690
Ausgegebene Aktien
70.588.959
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-1,86
Gewinn pro Aktie (EPS)
-1,88
Erlöse
20,76M
Nettogewinn
-132,49M

Über C4 Therapeutics Inc

C4 Therapeutics Inc is a bio-pharmaceutical company. The company is focused on harnessing the body's natural regulation of protein levels to develop novel therapeutic candidates to eliminate disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. C4 Therapeutics Inc is a bio-pharmaceutical company. The company is focused on harnessing the body's natural regulation of protein levels to develop novel therapeutic candidates to eliminate disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases.

Sektor
Biological Pds,ex Diagnstics
Branche
Biological Pds,ex Diagnstics
Website
www.c4therapeutics.com
Hauptsitz
Wilmington, Delaware, USA
Gegründet
-
C4 Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker CCCC. The last closing price for C4 Therapeutics was US$3,67. Over the last year, C4 Therapeutics shares have traded in a share price range of US$ 3,43 to US$ 11,88.

C4 Therapeutics currently has 70.588.959 shares in issue. The market capitalisation of C4 Therapeutics is US$258,71 million. C4 Therapeutics has a price to earnings ratio (PE ratio) of -1.86.

CCCC Neueste Nachrichten

Weitere Nachrichten

C4 Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

WATERTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation...

08 Januar 2025
GlobeNewswire Inc.

Form 8-K - Current report

09 Dezember 2024
Edgar (US Regulatory)

C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

In Multiple Myeloma, Cemsidomide in Combination with Dexamethasone at Highest Dose Level Explored to Date Achieved 36 Percent Overall Response Rate (ORR) and 45 Percent Clinical Benefit Rate...

08 Dezember 2024
GlobeNewswire Inc.

Form 8-K - Current report

20 November 2024
Edgar (US Regulatory)

C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors

Hoerter Brings Over Three Decades of Oncology Commercialization and Leadership Experience Appointment Underscores Continued Transformation of Board to Lead C4T into Next Phase of Pipeline Progress...

20 November 2024
GlobeNewswire Inc.

Form 144 - Report of proposed sale of securities

18 November 2024
Edgar (US Regulatory)

Form 424B3 - Prospectus [Rule 424(b)(3)]

15 November 2024
Edgar (US Regulatory)

Form 424B5 - Prospectus [Rule 424(b)(5)]

15 November 2024
Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

14 November 2024
Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

14 November 2024
Edgar (US Regulatory)
Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1-0.505-12.67252195733.9854.263.45617462913.87442562CS
4-0.795-18.59649122814.2754.533.4319105103.87813854CS
12-2.85-45.02369668256.336.523.4314366904.41558497CS
26-2.26-39.37282229975.747.663.4312776695.31773004CS
52-3.425-49.60173787116.90511.883.4317556746.37178953CS
156-26.68-88.461538461530.1630.561.0621403015.75471653CS
260-23.12-86.917293233126.651.211.0616103737.93917682CS

CCCC - Frequently Asked Questions (FAQ)

What is the current C4 Therapeutics share price?
The current share price of C4 Therapeutics is US$ 3,48
How many C4 Therapeutics shares are in issue?
C4 Therapeutics has 70.588.959 shares in issue
What is the market cap of C4 Therapeutics?
The market capitalisation of C4 Therapeutics is USD 258,71M
What is the 1 year trading range for C4 Therapeutics share price?
C4 Therapeutics has traded in the range of US$ 3,43 to US$ 11,88 during the past year
What is the PE ratio of C4 Therapeutics?
The price to earnings ratio of C4 Therapeutics is -1,86
What is the cash to sales ratio of C4 Therapeutics?
The cash to sales ratio of C4 Therapeutics is 11,87
What is the reporting currency for C4 Therapeutics?
C4 Therapeutics reports financial results in USD
What is the latest annual turnover for C4 Therapeutics?
The latest annual turnover of C4 Therapeutics is USD 20,76M
What is the latest annual profit for C4 Therapeutics?
The latest annual profit of C4 Therapeutics is USD -132,49M
What is the registered address of C4 Therapeutics?
The registered address for C4 Therapeutics is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the C4 Therapeutics website address?
The website address for C4 Therapeutics is www.c4therapeutics.com
Which industry sector does C4 Therapeutics operate in?
C4 Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Beweger

Alle Anzeigen
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
PHIOPhio Pharmaceuticals Corporation
US$ 6,50
(284,62%)
281,98M
SLRXSalarius Pharmaceuticals Inc
US$ 3,65
(133,23%)
120,26M
VRMEVerifyMe Inc
US$ 4,1575
(63,04%)
57,6M
ATPCAgape ATP Corporation
US$ 1,9645
(55,91%)
84,16M
AVGRAvinger Inc
US$ 0,8248
(46,47%)
9,78M
EHGOEshallgo Inc
US$ 1,2408
(-62,06%)
6,74M
CMTLComtech Telecommunications Corporation
US$ 2,3491
(-43,12%)
4,37M
SVMHSRIVARU Holding Ltd
US$ 0,0352
(-43,04%)
184,27M
LAESSEALSQ Corporation
US$ 3,35
(-41,54%)
89,92M
NMHINatures Miracle Holding Inc
US$ 1,12
(-38,80%)
735,08k
GCTKGlucoTrack Inc
US$ 0,1493
(27,61%)
685,02M
PHIOPhio Pharmaceuticals Corporation
US$ 6,50
(284,62%)
281,98M
BHATBlue Hat Interactive Entertainment Technology
US$ 0,0627
(-28,83%)
232,25M
NVDANVIDIA Corporation
US$ 133,23
(-1,97%)
204,68M
RGTIRigetti Computing Inc
US$ 6,0344
(-32,43%)
192,21M

Foren

Foren anzeigen
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

NASDAQ
CCCC
C4 Therapeutics
BIT
P1T8L0
BNP Paribas Issuance
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten